|
Chronic obstructive pulmonary disease (COPD), due to the presence of chronic bronchitis and emphysema, is the most prevalent clinical disorder associated with alpha1-antitrypsin (AAT) deficiency. Chronic bronchitis is defined on a clinical basis as a chronic productive cough, occurring for more than 3 months per year in each of 2 successive years.
The frequency of asthma in AAT-deficient individuals has been reported to be between 4% to 34%.1
Bronchiectasis may also occur with AAT deficiency, occurring in 5% to 10% of all patients.1
Typical Symptoms of AAT Deficiency-Associated Lung Disease
|
|
|
|
|
|
|
|
|
|
Shortness of breath following activity |
|
|
|
Decreased exercise tolerance |
|
|
|
Wheezing, with or without the presence of an upper respiratory infection |
|
|
|
Cough |
|
|
|
Excess sputum production |
|
|
|
Frequent lower respiratory tract infections |
|
|
|
History of suspected allergies and/or asthma |
|
|
|
|
|
References:
| 1. |
|
Bulletin of the World Health Organization: Alpha1-antitrypsin deficiency: Memorandum from a WHO meeting. 1997;75(5):397-415. |
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|